Revenue segments as reported by the company.

Pharmacy revenues

Premiums

Fees and other revenues

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Pharmacy and other service costs

Medical costs and other benefit expenses

Selling, general and administrative expenses

Amortization of acquired intangible assets

Special items

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cigna

Express Scripts is a company that provides integrated pharmacy benefit management services including network-pharmacy claims processing; home delivery pharmacy services; specialty pharmacy benefit management, through its subsidiary Accredo; benefit-design consultation; drug-utilization review; formulary management; and medical and drug data analysis services to manage drug plans for health plans, self-insured employers and government agencies (both as administrator of employee benefits and public assistance programs). Express Scripts also offers pharmacy benefit management services for workers' compensation insurance programs. The program is accredited by URAC, the nation's largest accrediting body for pharmacy benefit management companies. The company processes pharmaceutical claims for members through a network of retail pharmacies. Its own automated pharmacies dispense long-term, chronic medications-like those for diabetes or heart disease-directly to members by home delivery.

Express Scripts

The Cigna Group is a global health company, which engages in the provision of global health services. It operates through the following segments: Evernorth Health Services, Cigna Healthcare, Other Operations, and Corporate. The Evernorth Health Services segment partners with health plans, employers, governmental organizations, and health care providers to solve challenges in the areas of pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty distribution, and care delivery and management solutions. The Cigna Healthcare segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. The Other Operations segment consists of the remainder of business operations, which includes certain ongoing businesses and exited businesses. The Corporate segment refers to net interest expense, certain litigation matters, expense associated with frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments. The company was founded in 1792 and is headquartered in Bloomfield, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cigna posts strong Q4 earnings, eyes growth in specialized services

Cigna delivered strong financial results in Q4 2022, with robust revenue growth and operational performance across key business segments.
While facing challenges such as margin pressures and potential disenrollment, Cigna is well-positioned to capitalize on growth opportunities in 2023.
Strategic partnerships, customer-focused strategies, and financial discipline underscore Cigna's commitment to sustainable growth and shareholder value creation.
Investments in innovation, care coordination, and market expansion signal a proactive approach to navigating industry dynamics and driving future success.

Cigna reports robust Q1 earnings, eyes growth amid challenges

Cigna's Q1 2023 showcased strong financials, growth in key segments, and increased outlook.
Challenges include economic softening impact and margin expectations for the year.
Opportunities lie in customer relationships, innovation, and market-specific strategies.
Overall, Cigna remains confident in delivering on its financial and growth targets.

Cigna reports robust Q2 results, eyes growth through innovation

Cigna's Q2 2023 performance was strong, with revenue growth, customer expansion, and technological advancements driving positive outcomes.
While facing challenges like disenrollment and risk adjustment payables, Cigna is leveraging strengths in technology and cross-selling for growth.
Opportunities lie in partnerships like VillageMD, continued innovation, and strategic bidding strategies for future growth.
Overall, Cigna remains confident in delivering on adjusted EPS outlook for 2023 and 2024, with a focus on innovation and growth.

Cigna surpasses Q3 expectations, eyes $28 EPS in 2024

Cigna's Q3 performance exceeded expectations, driven by strong revenue and EPS growth across key business segments.
Strategic focus on innovation, affordability, and client partnerships positions Cigna well for future growth and value creation.
Challenges in margin expectations and enrollment declines require proactive management and strategic decision-making.
Opportunities lie in continued growth projections, strategic investments, and enhancing healthcare affordability and accessibility.

Cigna reports robust Q4 performance, eyes growth amid strategic changes

Cigna Group's Q4 2023 Earnings Call highlighted strong financial performance, leadership changes, and strategic decisions. Analyst inquiries focused on growth drivers, market outlook, and internal healthcare spend management. The outlook for 2024 includes expectations of solid adjusted EPS, revenue growth, and operating cash flow.

Cigna surpasses Q1 expectations, eyes growth through AI and biosimilars

Cigna's Q1 performance exceeded expectations, driven by strong revenue and EPS figures.
Despite challenges like noncash losses and disruptions, Cigna's strategic strengths in AI, biosimilars, and value-based care position it well for growth.
Opportunities in AI-driven healthcare solutions, biosimilar expansions, and strategic M&A offer avenues for future growth.
Cigna's focus on precision care solutions and client outcomes showcases its commitment to innovation and efficiency.

Cigna (CI) posts robust Q2 results, eyes biosimilar growth

Cigna (CI) reports strong Q2 financial results driven by Evernorth Health Services and Express Scripts' innovative programs.
Focus on affordability, access, and behavioral health services propels growth in U.S. employer business.
Challenges include navigating healthcare cost pressures and ensuring fair pricing negotiations.
Opportunities lie in biosimilar growth, sustainable revenue outlook, and strategic Medicare Advantage business sale.

Cigna reports robust Q3 earnings, eyes growth opportunities in 2025

Cigna's Q3 earnings call highlighted strong financial performance, strategic focus on shareholder value, and challenges in specialty drugs and cost trends. The company is optimistic about opportunities in 2025 and remains committed to delivering shareholder value through strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BLOOMFIELD, Conn. , Apr. 12, 2023 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its first quarter 2023 financial results on Friday, May 5, 2023, and will host a conference call the same day.

The Cigna Group's First Quarter 2023 Earnings Release Details

Advance Auto Parts

Accenture Plc

Automatic Data Processing

Ball Corp

British American Tobacco

Boston Properties

Carlisle Companies

Coterra Energy

Chevron

EOG Resources

Energy Transfer LP Unit

Johnson & Johnson

Lennar

MPLX

Merck

Morgan Stanley

Microsoft

NRG Energy

Pfizer

Southern Copper

Stanley Black & Decker

Target

Taiwan Semiconductor Manufacturing

Tyson Foods

This article is part of our monthly series where we highlight five companies that are large-cap, relatively safe, dividend-paying, and are offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks.

5 Relatively Safe And Cheap Dividend Stocks To Invest In - April 2023

UnitedHealth Group

Raymond James, an investment bank, recently upgraded two health insurance stocks in response to a better-than-expected Medicare payment increase scheduled for next year. UnitedHealth Group is America's largest health insurance benefits manager, and it's also becoming one of the country's largest employers of healthcare providers.

2 Reliable Dividend Stocks That Could Climb 24% to 32% According to Wall Street

AbbVie

AmerisourceBergen

Best Buy

ConocoPhillips

Cisco Systems

CVS Health

Dell Technologies

Devon Energy

eBay

Expeditors International of Washington

Twenty-First Century Fox

Gilead Sciences

KLA-Tencor

Lam Research

McKesson

Altria

Mosaic

Marathon Petroleum

Nutrien

Nucor

QUALCOMM

The following is a dividend portfolio strategy for large caps that score the highest amongst Joel Greenblatt's Magic Formula screener. The list follows large caps that have dividends.

Magic Formula Dividend Portfolio For April

The US managed care industry has strong tailwinds due to population growth, aging, and new care developments. The biggest risk for the industry is the introduction of the single-payer system with an estimated probability of 1-2% per election cycle.

Cigna: Do Not Miss The Moment

Domino's Pizza

Lowe's

Mastercard

MarketAxess Holdings

Monolithic Power Systems

Rollins

Charles Schwab

Sherwin-Williams

SS&C Technologies Hlds

Tractor Supply

Visa

W. R. Berkley

Zoetis

I present my top 15 high-growth dividend stocks to consider during the month of April. The watchlist posted a gain of 2.02% in March, finishing ahead of VIG but trailing SPY.

My Top 15 High-Growth Dividend Stocks For April 2023

Cigna (CI) remains well-poised for growth on the back of continually growing premiums within its Cigna Healthcare unit. Solid cash-generating abilities also enable it to deploy capital.

Here's Why Investors Should Retain Cigna (CI) Stock Now

-Axena Health, Inc. (Axena Health), a medical device company relentlessly dedicated to women's health, today announced that Cigna Healthcare (Cigna), one of the largest healthcare insurance providers in the United States with approximately 15 million members, has added the Leva Pelvic Health System as a covered treatment for stress, urgency and mixed urinary incontinence (UI) in women

Axena Health Receives Positive Insurance Coverage Decision From Cigna Healthcare for Leva Pelvic Health System

Deere & Company

Invitation Homes

Vanguard Dividend Appreciation ETF

This article will focus on DGI stocks that are likely to provide a high rate of dividend growth rather than a high current yield. We use our proprietary models to rate quantitatively and qualitatively and select the top ten names out of an initial list of nearly 400 dividend stocks.

Our Top 10 Dividend Growth Stocks - March 2023

Centene

Humana

Molina Healthcare

Improved premiums cropping from a solid customer base might aid the Medical-HMO industry. However, an escalating expense level and an acute shortage of nurses are roadblocks.

5 HMO Stocks to Watch Despite Elevated Tech Costs, Nursing Shortage

Cigna (CI) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Is Trending Stock Cigna Group (CI) a Buy Now?

MSCI

I present my top 15 high-growth dividend stocks to consider during the month of March. The watchlist posted loss of 2.94% in February, finishing behind VIG and SPY on the month.

My Top 15 High-Growth Dividend Stocks For March 2023

Despite delivering strong results, Cigna's stock has been underperforming the S&P, leading investors to question whether the company is undervalued. Cigna's strategic partnerships, geographic expansion, and strong financial position make it well-positioned for future growth.

Uncovering The Hidden Value In Cigna: A Thorough DCF Valuation

Apple

What is a blue chip company? When an asset is valuable and highly sought after, it might earn the term "blue chip.

What is a Blue Chip Company? Examples of Blue Chips

News for Cigna Stock (CI)